Anant Vinjamoori, MD

Today you can get a first look at Peptides+, our new specialty built around a clinically guided protocol and ongoing clinical support. We’ve been building for this. Join the list to be among the first in line when we launch: hims.com/peptides-plus

Important disclaimers here: news.hims.com/disclaimers/ca…

At Hims & Hers, we’re encouraged to see the administration make meaningful progress towards expanding access to peptide therapies through this draft interim policy. As more and more Americans seek these treatments, it is critical to have regulated channels, clinician oversight, quality standards, and transparency - none of which exist in the current gray market.

Our goal has always been to define what responsible access to care looks like. We have spent years building the infrastructure we need in our very own US-based peptide manufacturing facility, developing dosing protocols with clinical experts, and setting up frameworks to better understand these emerging treatments.

We'll keep working to bring these treatments within reach of those who need them, with more news to come soon.

Just wrapped a meeting with OIRA on HHS’s Interim Access Policy for Compounding Using Certain Peptides, and we’re grateful for the opportunity to discuss what regulated access to peptides should look like.

Let’s be clear: Countless Americans are already using peptides right now and the current environment isn’t serving them. Most are buying from unregulated gray markets, unvetted online retailers, or even at corner stores. They’re often getting products labeled ‘for research only’ or ‘for animal use,’ made entirely overseas under conditions no one can verify. These channels provide no real clinical oversight, no quality standards, and no record of what happened to the patient.

Peptide therapies hold meaningful potential to help millions of Americans live healthier lives, but only if they come with responsible, regulated pathways to care. Patients should be able to access peptides through licensed healthcare professionals providing ongoing clinical support, and US-based compounding, with active ingredients sourced from FDA-registered facilities. That’s how we’re building at Hims & Hers. That’s the standard for access we want to help set nationwide.

We appreciate the administration’s leadership in opening this path towards regulated peptide access, and look forward to seeing the interim policy move ahead.